SEARCH

SEARCH BY CITATION

References

  • Adalbert, R., Gilley, J. & Coleman, M.P. (2007) Abeta, tau and ApoE4 in Alzheimer’s disease: the axonal connection. Trends Mol Med 13, 135142.
  • Akatsu, H., Yamagata, H.D., Kawamata, J., Kamino, K., Takeda, M., Yamamoto, T., Miki, T., Tooyama, I., Shimohama, S. & Kosaka, K. (2006) Variations in the BDNF gene in autopsy-confirmed Alzheimer’s disease and dementia with Lewy bodies in Japan. Dement Geriatr Cogn Disord 22, 216222.
  • Allen, S.J., Wilcock, G.K. & Dawbarn, D. (1999) Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer’s disease. Biochem Biophys Res Commun 264, 648651.
  • Ambree, O., Leimer, U., Herring, A., Gortz, N., Sachser, N., Heneka, M.T., Paulus, W. & Keyvani, K. (2006) Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways. Am J Pathol 169, 544552.
  • Araujo, D.M. & Cotman, C.W. (1992) Basic FGF in astroglial, microglial, and neuronal cultures: characterization of binding sites and modulation of release by lymphokines and trophic factors. J Neurosci 12, 16681678.
  • Arenas, E. & Persson, H. (1994) Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature 367, 368371.
  • Arendt, T., Bigl, V., Arendt, A. & Tennstedt, A. (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease. Acta Neuropathol (Berl) 61, 101108.
  • Babu, J.R., Geetha, T. & Wooten, M.W. (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94, 192203.
  • Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R.S., Harlan, J., Barlow, E., Ebert, U. & Hillen, H. (2005) Globular amyloid beta-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem 95, 834847.
  • Bauer, M., Alda, M., Priller, J. & Young, L.T. (2003) Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36 (Suppl. 3), S250S254.
  • Bergeron, C., Pollanen, M.S., Weyer, L. & Lang, A.E. (1997) Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol 56, 726734.
  • Bian, J.T., Zhang, J.W., Zhang, Z.X. & Zhao, H.L. (2005) Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer’s disease (AD) in mainland Chinese. Neurosci Lett 387, 1116.
  • Boissiere, F., Hunot, S., Faucheux, B., Hersh, L.B., Agid, Y. & Hirsch, E.C. (1997) Trk neurotrophin receptors in cholinergic neurons of patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 8, 18.
  • Braak, H. & Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239259.
  • Brendza, R.P., Simmons, K., Bales, K.R., Paul, S.M., Goldberg, M.P. & Holtzman, D.M. (2003) Use of YFP to study amyloid-beta associated neurite alterations in live brain slices. Neurobiol Aging 24, 10711077.
  • Burack, M.A. & Halpain, S. (1996) Site-specific regulation of Alzheimer-like tau phosphorylation in living neurons. Neuroscience 72, 167184.
  • Burbach, G.J., Hellweg, R., Haas, C.A., Del Turco, D., Deicke, U., Abramowski, D., Jucker, M., Staufenbiel, M. & Deller, T. (2004) Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci 24, 24212430.
  • Busciglio, J., Lorenzo, A., Yeh, J. & Yankner, B.A. (1995) Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14, 879888.
  • Butt, A.M. & Dinsdale, J. (2005) Fibroblast growth factor 2 mediated disruption of myelin-forming oligodendrocytes in vivo is associated with increased tau immunoreactivity. Neurosci Lett 375, 2832.
  • Capsoni, S., Giannotta, S. & Cattaneo, A. (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 99, 1243212437.
  • Carlson, G.A., Borchelt, D.R., Dake, A., Turner, S., Danielson, V., Coffin, J.D., Eckman, C., Meiners, J., Nilsen, S.P., Younkin, S.G. & Hsiao, K.K. (1997) Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum Mol Genet 6, 19511959.
  • Chee, F.C., Mudher, A., Cuttle, M.F., Newman, T.A., MacKay, D., Lovestone, S. & Shepherd, D. (2005) Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis 20, 918928.
  • Chen, M.J. & Russo-Neustadt, A.A. (2005) Exercise activates the phosphatidylinositol 3-kinase pathway. Brain Res Mol Brain Res 135, 181193.
  • Cheng, B. & Mattson, M.P. (1992) Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bFGF. Exp Neurol 117, 114123.
  • Chu, Y., Cochran, E.J., Bennett, D.A., Mufson, E.J. & Kordower, J.H. (2001) Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer’s disease. J Comp Neurol 437, 296307.
  • Chuang, D.M. (2004) Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 16, 8390.
  • Chuu, J.Y., Taylor, J.L., Tinklenberg, J., Noda, A., Yesavage, J. & Murphy, G.M. Jr (2006) The brain-derived neurotrophic factor Val66Met polymorphism and rate of decline in Alzheimer’s disease. J Alzheimers Dis 9, 4349.
  • Cirrito, J.R., Yamada, K.A., Finn, M.B., Sloviter, R.S., Bales, K.R., May, P.C., Schoepp, D.D., Paul, S.M., Mennerick, S. & Holtzman, D.M. (2005) Synaptic activity regulates interstitial fluid amyloid-b levels in vivo. Neuron 48, 913922.
  • Combarros, O., Infante, J., Llorca, J. & Berciano, J. (2004) Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer’s disease. Dement Geriatr Cogn Disord 18, 5558.
  • Connor, B., Young, D., Lawlor, P., Gai, W., Waldvogel, H., Faull, R.L. & Dragunow, M. (1996) Trk receptor alterations in Alzheimer’s disease. Brain Res Mol Brain Res 42, 117.
  • Connor, B., Young, D., Yan, Q., Faull, R.L., Synek, B. & Dragunow, M. (1997) Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain Res 49, 7181.
  • Costantini, C., Weindruch, R., Della Valle, G. & Puglielli, L. (2005) A TrkA-to-p75NTR molecular switch activates amyloid beta-peptide generation during aging. Biochem J 391, 5967.
  • Costantini, C., Scrable, H. & Puglielli, L. (2006) An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide generation. EMBO J 25, 19972006.
  • Counts, S.E., Nadeem, M., Wuu, J., Ginsberg, S.D., Saragovi, H.U. & Mufson, E.J. (2004) Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer’s disease. Ann Neurol 56, 520531.
  • Crutcher, K.A., Scott, S.A., Liang, S., Everson, W.V. & Weingartner, J. (1993) Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer’s disease. J Neurosci 13, 25402550.
  • Cummings, B.J., Su, J.H. & Cotman, C.W. (1993) Neuritic involvement within bFGF immunopositive plaques of Alzheimer’s disease. Exp Neurol 124, 315325.
  • Da Penha Berzaghi, M., Cooper, J., Castrén, E., Zafra, F., Sofroniew, M., Thoenen, H. & Lindholm, D. (1993) Cholinergic regulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) but not neurotrophin-3 (NT-3) mRNA levels in the developing rat hippocampus. J Neurosci 13, 38133826.
  • Delacourte, A., Sergeant, N., Champain, D., Wattez, A., Maurage, C.A., Lebert, F., Pasquier, F. & David, J.P. (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease. Neurology 59, 398407.
  • De Rosa, R., Garcia, A.A., Braschi, C., Capsoni, S., Maffei, L., Berardi, N. & Cattaneo, A. (2005) Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A 102, 38113816.
  • Desai, P., Nebes, R., DeKosky, S.T. & Kamboh, M.I. (2005) Investigation of the effect of brain-derived neurotrophic factor (BDNF) polymorphisms on the risk of late-onset Alzheimer’s disease (AD) and quantitative measures of AD progression. Neurosci Lett 379, 229234.
  • Durany, N., Michel, T., Kurt, J., Cruz-Sanchez, F.F., Cervas-Navarro, J. & Riederer, P. (2000) Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer’s disease brains. Int J Dev Neurosci 18, 807813.
  • Elliott, E. & Ginzburg, I. (2006) The role of neurotrophins and insulin on tau pathology in Alzheimer’s disease. Rev Neurosci 17, 635642.
  • Elliott, E., Atlas, R., Lange, A. & Ginzburg, I. (2005) Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 kinase signalling mechanism. Eur J Neurosci 22, 10811089.
  • Fahnestock, M., Scott, S.A., Jette, N., Weingartner, J.A. & Crutcher, K.A. (1996) Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer’s disease parietal cortex. Brain Res Mol Brain Res 42, 175178.
  • Fahnestock, M., Michalski, B., Xu, B. & Coughlin, M.D. (2001) The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer’s disease. Mol Cell Neurosci 18, 210220.
  • Ferrer, I. & Marti, E. (1998) Distribution of fibroblast growth factor receptor-1 (FGFR-1) and FGFR-3 in the hippocampus of patients with Alzheimer’s disease. Neurosci Lett 240, 139142.
  • Ferrer, I., Marin, C., Rey, M.J., Ribalta, T., Goutan, E., Blanco, R., Tolosa, E. & Marti, E. (1999) BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 58, 729739.
  • Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P.R., Rimmer, E. & Scazufca, M. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 21122117.
  • Fisher, A., Heldman, E., Gurwitz, D., Haring, R., Karton, Y., Meshulam, H., Pittel, Z., Marciano, D., Brandeis, R., Sadot, E., Barg, Y., Pinkas-Kramarski, R., Vogel, Z., Ginzburg, I., Treves, T.A., Verchovsky, R., Klimowsky, S. & Korczyn, A.D. (1996) M1 agonists for the treatment of Alzheimer’s disease. Novel properties and clinical update. Ann N Y Acad Sci 777, 189196.
  • Forero, D.A., Benitez, B., Arboleda, G., Yunis, J.J., Pardo, R. & Arboleda, H. (2006) Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND UCHL1) in Alzheimer’s disease in Colombia. Neurosci Res 55, 334341.
  • Frey, B.N., Andreazza, A.C., Cereser, K.M., Martins, M.R., Valvassori, S.S., Reus, G.Z., Quevedo, J. & Kapczinski, F. (2006a) Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 79, 281286.
  • Frey, B.N., Andreazza, A.C., Rosa, A.R., Martins, M.R., Valvassori, S.S., Reus, G.Z., Hatch, J.P., Quevedo, J. & Kapczinski, F. (2006b) Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania. Behav Pharmacol 17, 311318.
  • Friedman, W.J. (2000) Neurotrophins induce death of hippocampal neurons via the p75 receptor. J Neurosci 20, 63406346.
  • Garzon, D., Yu, G. & Fahnestock, M. (2002) A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer’s disease parietal cortex. J Neurochem 82, 10581064.
  • Garzon, D.J. & Fahnestock, M. (2007) Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 27, 26282635.
  • Ge, Y.W. & Lahiri, D.K. (2002) Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer’s disease. Ann N Y Acad Sci 973, 463467.
  • Giacobini, E. (2003) Cholinesterases: new roles in brain function and in Alzheimer’s disease. Neurochem Res 28, 515522.
  • Ginsberg, S.D., Che, S., Counts, S.E. & Mufson, E.J. (2006a) Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. J Neurochem 96, 14011408.
  • Ginsberg, S.D., Che, S., Wuu, J., Counts, S.E. & Mufson, E.J. (2006b) Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer’s disease. J Neurochem 97, 475487.
  • Goedert, M., Fine, A., Hunt, S.P. & Ullrich, A. (1986) Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer’s disease. Brain Res 387, 8592.
  • Goedert, M., Fine, A., Dawbarn, D., Wilcock, G.K. & Chao, M.V. (1989) Nerve growth factor receptor mRNA distribution in human brain: normal levels in basal forebrain in Alzheimer’s disease. Brain Res Mol Brain Res 5, 17.
  • Goldsbury, C., Mocanu, M.M., Thies, E., Kaether, C., Haass, C., Keller, P., Biernat, J., Mandelkow, E. & Mandelkow, E.M. (2006) Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides. Traffic 7, 873888.
  • Gomez-Pinilla, F., Cummings, B.J. & Cotman, C.W. (1990) Induction of basic fibroblast growth factor in Alzheimer’s disease pathology. Neuroreport 1, 211214.
  • Gunawardena, S. & Goldstein, L.S. (2001) Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32, 389401.
  • Hanneken, A., Frautschy, S., Galasko, D. & Baird, A. (1995) A fibroblast growth factor binding protein in human cerebral spinal fluid. Neuroreport 6, 886888.
  • Hardy, J. & Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12, 383388.
  • Hashimoto, Y., Kaneko, Y., Tsukamoto, E., Frankowski, H., Kouyama, K., Kita, Y., Niikura, T., Aiso, S., Bredesen, D.E., Matsuoka, M. & Nishimoto, I. (2004) Molecular characterization of neurohybrid cell death induced by Alzheimer’s amyloid-beta peptides via p75NTR/PLAIDD. J Neurochem 90, 549558.
  • Hasselmo, M.E. & Stern, C.E. (2006) Mechanisms underlying working memory for novel information. Trends Cogn Sci 10, 487493.
  • Heese, K., Hock, C. & Otten, U. (1998) Inflammatory signals induce neurotrophin expression in human microglial cells. J Neurochem 70, 699707.
  • Hellweg, R. & Jockers-Scherubl, M. (1994) Neurotrophic factors in memory disorders. Life Sci 55, 21652169.
  • Hellweg, R., Gericke, C.A., Jendroska, K., Hartung, H.D. & Cervos-Navarro, J. (1998) NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer’s disease. Int J Dev Neurosci 16, 787794.
  • Hellweg, R., Lohmann, P., Huber, R., Kuhl, A. & Riepe, M.W. (2006) Spatial navigation in complex and radial mazes in APP23 animals and neurotrophin signaling as a biological marker of early impairment. Learn Mem 13, 6371.
  • Heneka, M.T. & O’Banion, M.K. (2007) Inflammatory processes in Alzheimer’s disease. J Neuroimmunol 184, 6991.
  • Hiruma, H., Katakura, T., Takahashi, S., Ichikawa, T. & Kawakami, T. (2003) Glutamate and amyloid beta-protein rapidly inhibit fast axonal transport in cultured rat hippocampal neurons by different mechanisms. J Neurosci 23, 89678977.
  • Hock, C., Heese, K., Muller-Spahn, F., Hulette, C., Rosenberg, C. & Otten, U. (1998) Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer’s disease. Neurosci Lett 241, 151154.
  • Hock, C., Heese, K., Hulette, C., Rosenberg, C. & Otten, U. (2000a) Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57, 846851.
  • Hock, C., Heese, K., Muller-Spahn, F., Huber, P., Riesen, W., Nitsch, R.M. & Otten, U. (2000b) Increased cerebrospinal fluid levels of neurotrophin 3 (NT-3) in elderly patients with major depression. Mol Psychiatry 5, 510513.
  • Hofman, A., Rocca, W.A., Brayne, C., Breteler, M.M., Clarke, M., Cooper, B., Copeland, J.R., Dartigues, J.F., Da Silva Droux, A., Hagnell, O., Heere, T.J., Engedal, K., Jonker, C., Lindsay, J., Lobo, A., Mann, A.H., Mölsä, P.K., Morgan, K., O’Connor, D.W., Sulkava, R., Kay, D.W.K., Amaducci, L. & For The Euroderm Prevalence Research Group. (1991) The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol 20, 736748.
  • Holsinger, R.M., Schnarr, J., Henry, P., Castelo, V.T. & Fahnestock, M. (2000) Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Brain Res Mol Brain Res 76, 347354.
  • Hu, X.Y., Zhang, H.Y., Qin, S., Xu, H., Swaab, D.F. & Zhou, J.N. (2002) Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients. Exp Neurol 178, 104111.
  • Huang, R., Huang, J., Cathcart, H., Smith, S. & Poduslo, S.E. (2007) Genetic variants in brain-derived neurotrophic factor associated with Alzheimer’s disease. J Med Genet 44 e66.
  • Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M.K., Trojanowski, J.Q. & Lee, V.M. (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751762.
  • Jankowsky, J.L., Xu, G., Fromholt, D., Gonzales, V. & Borchelt, D.R. (2003) Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol 62, 12201227.
  • Jarvik, L. & Greenson, H. (1987) About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson). Alzheimer Dis Assoc Disord 1, 38.
  • Jette, N., Cole, M.S. & Fahnestock, M. (1994) NGF mRNA is not decreased in frontal cortex from Alzheimer’s disease patients. Brain Res Mol Brain Res 25, 242250.
  • Jin, K., Sun, Y., Xie, L., Batteur, S., Mao, X.O., Smelick, C., Logvinova, A. & Greenberg, D.A. (2003) Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in hippocampus and subventricular zone of aged mice. Aging Cell 2, 175183.
  • Johnson-Farley, N.N., Patel, K., Kim, D. & Cowen, D.S. (2007) Interaction of FGF-2 with IGF-1 and BDNF in stimulating Akt, ERK, and neuronal survival in hippocampal cultures. Brain Res 1154, 4049.
  • Kar, S., Slowikowski, S.P., Westaway, D. & Mount, H.T. (2004) Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J Psychiatry Neurosci 29, 427441.
  • Kasa, P., Rakonczay, Z. & Gulya, K. (1997) The cholinergic system in Alzheimer’s disease. Prog Neurobiol 52, 511535.
  • Kato, T., Sasaki, H., Katagiri, T., Sasaki, H., Koiwai, K., Youki, H., Totsuka, S. & Ishii, T. (1991) The binding of basic fibroblast growth factor to Alzheimer’s neurofibrillary tangles and senile plaques. Neurosci Lett 122, 3336.
  • Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W. & Glabe, C.G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486489.
  • Kerwin, J.M., Morris, C.M., Perry, R.H. & Perry, E.K. (1992) Hippocampal nerve growth factor receptor immunoreactivity in patients with Alzheimer’s and Parkinson’s disease. Neurosci Lett 143, 101104.
  • Kiprianova, I., Schindowski, K., Von Bohlen und Halbach, O., Krause, S., Dono, R., Schwaninger, M. & Unsicker, K. (2004) Enlarged infarct volume and loss of BDNF mRNA induction following brain ischemia in mice lacking FGF-2. Exp Neurol 189, 252260.
  • Klenk, J., Rapp, K., Buchele, G., Keil, U. & Weiland, S.K. (2007) Increasing life expectancy in Germany: quantitative contributions from changes in age- and disease-specific mortality. Eur J Public Health. doi: 10.1093/eurpub/ckm024.
  • Kokubo, H., Kayed, R., Glabe, C.G. & Yamaguchi, H. (2005) Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer’s disease brain. Brain Res 1031, 222228.
  • Kraemer, B.C., Zhang, B., Leverenz, J.B., Thomas, J.H., Trojanowski, J.Q. & Schellenberg, G.D. (2003) Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A 100, 99809985.
  • Kuner, P. & Hertel, C. (1998) NGF induces apoptosis in a human neuroblastoma cell line expressing the neurotrophin receptor p75NTR. J Neurosci Res 54, 465474.
  • Kunugi, H., Hattori, M., Ueki, A., Isse, K., Hirasawa, H. & Nanko, S. (1998) Possible association of missense mutation (Gly[-63]Glu) of the neurotrophin-3 gene with Alzheimer’s disease in Japanese. Neurosci Lett 241, 6567.
  • Kunugi, H., Ueki, A., Otsuka, M., Isse, K., Hirasawa, H., Kato, N., Nabika, T., Kobayashi, S. & Nanko, S. (2001) A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer’s disease. Mol Psychiatry 6, 8386.
  • Lang, U.E., Muhlbacher, M., Hesselink, M.B., Zajaczkowski, W., Danysz, W., Danker-Hopfe, H. & Hellweg, R. (2004) No nerve growth factor response to treatment with memantine in adult rats. J Neural Transm 111, 181190.
  • Lazarov, O., Lee, M., Peterson, D.A. & Sisodia, S.S. (2002) Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J Neurosci 22, 97859793.
  • Lazarov, O., Robinson, J., Tang, Y.P., Hairston, I.S., Korade-Mirnics, Z., Lee, V.M., Hersh, L.B., Sapolsky, R.M., Mirnics, K. & Sisodia, S.S. (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120, 701713.
  • Lee, E.B., Zhang, B., Liu, K., Greenbaum, E.A., Doms, R.W., Trojanowski, J.Q. & Lee, V.M. (2005a) BACE overexpression alters the subcellular processing of APP and inhibits Ab deposition in vivo. J Cell Biol 168, 291302.
  • Lee, J., Fukumoto, H., Orne, J., Klucken, J., Raju, S., Vanderburg, C.R., Irizarry, M.C., Hyman, B.T. & Ingelsson, M. (2005b) Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp Neurol 194, 9196.
  • Lesné, S., Gabriel, C., Nelson, D.A., White, E., Mackenzie, E.T., Vivien, D., Buisson, A. (2005) Akt-dependent expression of NAIP-1 protects neurons against amyloid-β toxicity. J Biol Chem 280, 2494124947.
  • Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Paul Murphy, M., Baker, M., Yu, X., Duff, K., Hardy, J., Corral, A., Lin, W.L., Yen, S.H., Dickson, D.W., Davies, P. & Hutton, M. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25, 402405.
  • Li, Y., Rowland, C., Tacey, K., Catanese, J., Sninsky, J., Hardy, J., Powell, J., Lovestone, S., Morris, J.C., Thal, L., Goate, A., Owen, M., Williams, J. & Grupe, A. (2005) The BDNF Val66Met polymorphism is not associated with late onset Alzheimer’s disease in three case-control samples. Mol Psychiatry 10, 809810.
  • Loy, R., Heyer, D., Clagett-Dame, M. & DiStefano, P.S. (1990) Localization of NGF receptors in normal and Alzheimer’s basal forebrain with monoclonal antibodies against the truncated form of the receptor. J Neurosci Res 27, 651664.
  • Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E. & Rogers, J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155, 853862.
  • Mahley, R.W., Weisgraber, K.H. & Huang, Y. (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci U S A 103, 56445651.
  • Mai, L., Jope, R.S. & Li, X. (2002) BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem 82, 7583.
  • Maloney, M.T., Minamide, L.S., Kinley, A.W., Boyle, J.A. & Bamburg, J.R. (2005) Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer’s disease. J Neurosci 25, 1131311321.
  • Mandelkow, E.M., Thies, E., Trinczek, B., Biernat, J. & Mandelkow, E. (2004) MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol 167, 99110.
  • Manji, H.K., Moore, G.J. & Chen, G. (1999) Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46, 929940.
  • Marvanova, M., Lakso, M., Pirhonen, J., Nawa, H., Wong, G. & Castren, E. (2001) The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 18, 247258.
  • Matsushita, S., Arai, H., Matsui, T., Yuzuriha, T., Urakami, K., Masaki, T. & Higuchi, S. (2005) Brain-derived neurotrophic factor gene polymorphisms and Alzheimer’s disease. J Neural Transm 112, 703711.
  • Michalski, B. & Fahnestock, M. (2003) Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease. Brain Res Mol Brain Res 111, 148154.
  • Mobley, W.C., Neve, R.L., Prusiner, S.B. & McKinley, M.P. (1988) Nerve growth factor increases mRNA levels for the prion protein and the beta-amyloid protein precursor in developing hamster brain. Proc Natl Acad Sci U S A 85, 98119815.
  • Mudher, A., Shepherd, D., Newman, T.A., Mildren, P., Jukes, J.P., Squire, A., Mears, A., Drummond, J.A., Berg, S., MacKay, D., Asuni, A.A., Bhat, R. & Lovestone, S. (2004) GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 9, 522530.
  • Mufson, E.J., Conner, J.M. & Kordower, J.H. (1995) Nerve growth factor in Alzheimer’s disease: defective retrograde transport to nucleus basalis. Neuroreport 6, 10631066.
  • Mufson, E.J., Lavine, N., Jaffar, S., Kordower, J.H., Quirion, R. & Saragovi, H.U. (1997) Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer’s disease. Exp Neurol 146, 91103.
  • Mufson, E.J., Ma, S.Y., Cochran, E.J., Bennett, D.A., Beckett, L.A., Jaffar, S., Saragovi, H.U. & Kordower, J.H. (2000) Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer’s disease. J Comp Neurol 427, 1930.
  • Mufson, E.J., Ma, S.Y., Dills, J., Cochran, E.J., Leurgans, S., Wuu, J., Bennett, D.A., Jaffar, S., Gilmor, M.L., Levey, A.I. & Kordower, J.H. (2002) Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer’s disease. J Comp Neurol 443, 136153.
  • Mufson, E.J., Ginsberg, S.D., Ikonomovic, M.D. & DeKosky, S.T. (2003) Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26, 233242.
  • Murase, K., Igarashi, K. & Hayashi, K. (1994) Neurotrophin-3 (NT-3) levels in the developing rat nervous system and in human samples. Clin Chim Acta 227, 2336.
  • Murer, M.G., Boissiere, F., Yan, Q., Hunot, S., Villares, J., Faucheux, B., Agid, Y., Hirsch, E. & Raisman-Vozari, R. (1999) An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer’s disease. Neuroscience 88, 10151032.
  • Murer, M.G., Yan, Q. & Raisman-Vozari, R. (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol 63, 71124.
  • Muresan, Z. & Muresan, V. (2006) Neuritic deposits of amyloid-b peptide in a subpopulation of central nervous system-derived neuronal cells. Mol Cell Biol 26, 49824997.
  • Nacmias, B., Piccini, C., Bagnoli, S., Tedde, A., Cellini, E., Bracco, L. & Sorbi, S. (2004) Brain-derived neurotrophic factor, apolipoprotein E genetic variants and cognitive performance in Alzheimer’s disease. Neurosci Lett 367, 379383.
  • Narisawa-Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H. & Nawa, H. (1996) Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer’s disease. Neuroreport 7, 29252928.
  • Nishimura, M., Kuno, S., Kaji, R. & Kawakami, H. (2005) Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer’s disease, Parkinson’s disease, and multiple system atrophy. Mov Disord 20, 10311033.
  • Nuydens, R., Dispersyn, G., De Jong, M., Van Den Kieboom, G., Borgers, M. & Geerts, H. (1997) Aberrant tau phosphorylation and neurite retraction during NGF deprivation in PC12 cells. Biochem Biophys Res Commun 240, 687691.
  • Olin, D., MacMurray, J. & Comings, D.E. (2005) Risk of late-onset Alzheimer’s disease associated with BDNF C270T polymorphism. Neurosci Lett 381, 275278.
  • Olivieri, G., Novakovic, M., Savaskan, E., Meier, F., Baysang, G., Brockhaus, M. & Muller-Spahn, F. (2002) The effects of beta-estradiol on SHSY5Y neuroblastoma cells during heavy metal induced oxidative stress, neurotoxicity and beta-amyloid secretion. Neuroscience 113, 849855.
  • Olivieri, G., Otten, U., Meier, F., Baysang, G., Dimitriades-Schmutz, B., Muller-Spahn, F. & Savaskan, E. (2003) Beta-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin. Neuroscience 120, 659665.
  • Origlia, N., Capsoni, S., Domenici, L. & Cattaneo, A. (2006) Time window in cholinomimetic ability to rescue long-term potentiation in neurodegenerating anti-nerve growth factor mice. J Alzheimers Dis 9, 5968.
  • Patapoutian, A. & Reichardt, L.F. (2001) Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 11, 272280.
  • Peng, S., Wuu, J., Mufson, E.J. & Fahnestock, M. (2004) Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 63, 641649.
  • Peng, S., Wuu, J., Mufson, E.J. & Fahnestock, M. (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem 93, 14121421.
  • Perry, E.K., Johnson, M., Kerwin, J.M., Piggott, M.A., Court, J.A., Shaw, P.J., Ince, P.G., Brown, A. & Perry, R.H. (1992) Convergent cholinergic activities in aging and Alzheimer’s disease. Neurobiol Aging 13, 393400.
  • Perry, E.K., Irving, D., Kerwin, J.M., McKeith, I.G., Thompson, P., Collerton, D., Fairbairn, A.F., Ince, P.G., Morris, C.M., Cheng, A.V., Perry, R.H. (1993) Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7, 6979.
  • Phillips, H.S., Hains, J.M., Armanini, M., Laramee, G.R., Johnson, S.A. & Winslow, J.W. (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron 7, 695702.
  • Pike, C.J., Cummings, B.J., Monzavi, R. & Cotman, C.W. (1994) Beta-amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer’s disease. Neuroscience 63, 517531.
  • Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinisto, L., Halonen, P. & Kontula, K. (1995) Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333, 12421247.
  • Probst, A., Gotz, J., Wiederhold, K.H., Tolnay, M., Mistl, C., Jaton, A.L., Hong, M., Ishihara, T., Lee, V.M., Trojanowski, J.Q., Jakes, R., Crowther, R.A., Spillantini, M.G., Burki, K. & Goedert, M. (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (Berl) 99, 469481.
  • Qiu, Z., Naten, D.L., Liston, J.C., Yess, J. & Rebeck, G.W. (2001) A novel approach for studying endogenous ab processing using cultured primary neurons isolated from APP transgenic mice. Exp Neurol 170, 186194.
  • Riemenschneider, M., Schwarz, S., Wagenpfeil, S., Diehl, J., Muller, U., Forstl, H. & Kurz, A. (2002) A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer’s disease in patients lacking the Apolipoprotein E epsilon4 allele. Mol Psychiatry 7, 782785.
  • Robakis, N.K., Anderson, J.P., Refolo, L.M. & Wallace, W. (1991) Expression of the Alzheimer amyloid precursor in brain tissue and effects of NGF and EGF on its metabolism. Clin Neuropharmacol 14 (Suppl. 1), S15S23.
  • Rossner, S., Ueberham, U., Schliebs, R., Perez-Polo, J.R. & Bigl, V. (1998) p75 and TrkA receptor signaling independently regulate amyloid precursor protein mRNA expression, isoform composition, and protein secretion in PC12 cells. J Neurochem 71, 757766.
  • Ruiz-Leon, Y. & Pascual, A. (2004) Regulation of beta-amyloid precursor protein expression by brain-derived neurotrophic factor involves activation of both the Ras and phosphatidylinositide 3-kinase signalling pathways. J Neurochem 88, 10101018.
  • Saarela, M.S., Lehtimaki, T., Rinne, J.O., Huhtala, H., Rontu, R., Hervonen, A., Roytta, M., Ahonen, J.P. & Mattila, K.M. (2006) No association between the brain-derived neurotrophic factor 196 G>A or 270 C>T polymorphisms and Alzheimer’s or Parkinson’s disease. Folia Neuropathol 44, 1216.
  • Sadot, E., Heicklen-Klein, A., Barg, J., Lazarovici, P. & Ginzburg, I. (1996) Identification of a tau promoter region mediating tissue-specific-regulated expression in PC12 cells. J Mol Biol 256, 805812.
  • Saez, E.T., Pehar, M., Vargas, M.R., Barbeito, L. & Maccioni, R.B. (2006) Production of nerve growth factor by beta-amyloid-stimulated astrocytes induces p75(NTR)-dependent tau hyperphosphorylation in cultured hippocampal neurons. J Neurosci Res 84, 10981106.
  • Salehi, A., Verhaagen, J., Dijkhuizen, P.A. & Swaab, D.F. (1996) Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer’s disease. Neuroscience 75, 373387.
  • Salehi, A., Ocampo, M., Verhaagen, J. & Swaab, D.F. (2000) P75 neurotrophin receptor in the nucleus basalis of meynert in relation to age, sex, and Alzheimer’s disease. Exp Neurol 161, 245258.
  • Salehi, A., Delcroix, J.D., Belichenko, P.V., Zhan, K., Wu, C., Valletta, J.S., Takimoto-Kimura, R., Kleschevnikov, A.M., Sambamurti, K., Chung, P.P., Xia, W., Villar, A., Campbell, W.A., Kulnane, L.S., Nixon, R.A., Lamb, B.T., Epstein, C.J., Stokin, G.B., Goldstein, L.S., Mobley, W.C. (2006) Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 2942.
  • Savaskan, E., Muller-Spahn, F., Olivieri, G., Bruttel, S., Otten, U., Rosenberg, C., Hulette, C. & Hock, C. (2000) Alterations in trk A, trk B and trk C receptor immunoreactivities in parietal cortex and cerebellum in Alzheimer’s disease. Eur Neurol 44, 172180.
  • Scott, S.A., Mufson, E.J., Weingartner, J.A., Skau, K.A. & Crutcher, K.A. (1995) Nerve growth factor in Alzheimer’s disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 15, 62136221.
  • Seitz, A., Kojima, H., Oiwa, K., Mandelkow, E.M., Song, Y.H. & Mandelkow, E. (2002) Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J 21, 48964905.
  • Selkoe, D.J. (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81, 741766.
  • Sergeant, N., Delacourte, A. & Buee, L. (2005) Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 1739, 179197.
  • Shelton, S.B. & Johnson, G.V. (2001) Tau and HMW tau phosphorylation and compartmentalization in apoptotic neuronal PC12 cells. J Neurosci Res 66, 203213.
  • Shen, Z.X. (2004) Brain cholinesterases: III. Future perspectives of AD research and clinical practice. Med Hypotheses 63, 298307.
  • Sheng, J.G., Price, D.L. & Koliatsos, V.E. (2002) Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Ab amyloidosis. J Neurosci 22, 97949799.
  • Siedlak, S.L., Cras, P., Kawai, M., Richey, P. & Perry, G. (1991) Basic fibroblast growth factor binding is a marker for extracellular neurofibrillary tangles in Alzheimer disease. J Histochem Cytochem 39, 899904.
  • Siegel, G.J. & Chauhan, N.B. (2000) Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain. Brain Res Brain Res Rev 33, 199227.
  • Sokol, D.K., Chen, D., Farlow, M.R., Dunn, D.W., Maloney, B., Zimmer, J.A. & Lahiri, D.K. (2006) High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 21, 444449.
  • Soto, I., Rosenthal, J.J., Blagburn, J.M. & Blanco, R.E. (2006) Fibroblast growth factor 2 applied to the optic nerve after axotomy up-regulates BDNF and TrkB in ganglion cells by activating the ERK and PKA signaling pathways. J Neurochem 96, 8296.
  • Stamer, K., Vogel, R., Thies, E., Mandelkow, E. & Mandelkow, E.M. (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156, 10511063.
  • Stieber, A., Mourelatos, Z. & Gonatas, N.K. (1996) In Alzheimer’s disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic. Am J Pathol 148, 415426.
  • Stokin, G.B., Lillo, C., Falzone, T.L., Brusch, R.G., Rockenstein, E., Mount, S.L., Raman, R., Davies, P., Masliah, E., Williams, D.S. & Goldstein, L.S. (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science 307, 12821288.
  • Svendsen, C.N., Cooper, J.D. & Sofroniew, M.V. (1991) Trophic factor effects on septal cholinergic neurons. Ann N Y Acad Sci 640, 9194.
  • Takahashi, R.H., Almeida, C.G., Kearney, P.F., Yu, F., Lin, M.T., Milner, T.A. & Gouras, G.K. (2004) Oligomerization of Alzheimer’s beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24, 35923599.
  • Takami, K., Matsuo, A., Terai, K., Walker, D.G., McGeer, E.G. & McGeer, P.L. (1998) Fibroblast growth factor receptor-1 expression in the cortex and hippocampus in Alzheimer’s disease. Brain Res 802, 8997.
  • Tatebayashi, Y., Iqbal, K. & Grundke-Iqbal, I. (1999) Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus. J Neurosci 19, 52455254.
  • Tatebayashi, Y., Lee, M.H., Li, L., Iqbal, K. & Grundke-Iqbal, I. (2003) The dentate gyrus neurogenesis: a therapeutic target for Alzheimer’s disease. Acta Neuropathol (Berl) 105, 225232.
  • Tatebayashi, Y., Haque, N., Tung, Y.C., Iqbal, K. & Grundke-Iqbal, I. (2004) Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport. J Cell Sci 117, 16531663.
  • Thoenen, H., Zafra, F., Hengerer, B. & Lindholm, D. (1991) The synthesis of nerve growth factor and brain-derived neurotrophic factor in hippocampal and cortical neurons is regulated by specific transmitter systems. Ann N Y Acad Sci 640, 8690.
  • Tong, L., Shen, H., Perreau, V.M., Balazs, R. & Cotman, C.W. (2001a) Effects of exercise on gene-expression profile in the rat hippocampus. Neurobiol Dis 8, 10461056.
  • Tong, L., Thornton, P.L., Balazs, R. & Cotman, C.W. (2001b) Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol Chem 276, 1730117306.
  • Tong, L., Balazs, R., Thornton, P.L. & Cotman, C.W. (2004) Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 24, 67996809.
  • Treanor, J.J., Dawbarn, D., Allen, S.J., MacGowan, S.H. & Wilcock, G.K. (1991) Low affinity nerve growth factor receptor binding in normal and Alzheimer’s disease basal forebrain. Neurosci Lett 121, 7376.
  • Tsai, J., Grutzendler, J., Duff, K. & Gan, W.B. (2004a) Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 7, 11811183.
  • Tsai, S.J., Hong, C.J., Liu, H.C., Liu, T.Y., Hsu, L.E. & Lin, C.H. (2004b) Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer’s disease and age of onset. Neuropsychobiology 49, 1012.
  • Tsai, S.J., Hong, C.J., Liu, H.C., Liu, T.Y. & Liou, Y.J. (2006) The brain-derived neurotrophic factor gene as a possible susceptibility candidate for Alzheimer’s disease in a Chinese population. Dement Geriatr Cogn Disord 21, 139143.
  • Tsukamoto, E., Hashimoto, Y., Kanekura, K., Niikura, T., Aiso, S. & Nishimoto, I. (2003) Characterization of the toxic mechanism triggered by Alzheimer’s amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells. J Neurosci Res 73, 627636.
  • Tuszynski, M.H., Smith, D.E., Roberts, J., McKay, H. & Mufson, E. (1998) Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate beta-amyloid plaque deposition. Exp Neurol 154, 573582.
  • Tuszynski, M.H., Thal, L., Pay, M., Salmon, D.P., U, H.S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H.L., Ho, G., Tong, G., Potkin, S.G., Fallon, J., Hansen, L., Mufson, E.J., Kordower, J.H., Gall, C. & Conner, J. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11, 551555.
  • Venero, J.L., Knusel, B., Beck, K.D. & Hefti, F. (1994) Expression of neurotrophin and trk receptor genes in adult rats with fimbria transections: effect of intraventricular nerve growth factor and brain-derived neurotrophic factor administration. Neuroscience 59, 797815.
  • Vepsalainen, S., Castren, E., Helisalmi, S., Iivonen, S., Mannermaa, A., Lehtovirta, M., Hanninen, T., Soininen, H. & Hiltunen, M. (2005) Genetic analysis of BDNF and TrkB gene polymorphisms in Alzheimer’s disease. J Neurol 252, 423428.
  • Verdile, G., Fuller, S., Atwood, C.S., Laws, S.M., Gandy, S.E. & Martins, R.N. (2004) The role of beta amyloid in Alzheimer’s disease: still a cause of everything or the only one who got caught? Pharmacol Res 50, 397409.
  • Villa, A., Latasa, M.J. & Pascual, A. (2001) Nerve growth factor modulates the expression and secretion of beta-amyloid precursor protein through different mechanisms in PC12 cells. J Neurochem 77, 10771084.
  • Wirths, O., Weis, J., Kayed, R., Saido, T.C. & Bayer, T.A. (2006) Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging 8, 16891699.
  • Wolf, S.A., Kronenberg, G., Lehmann, K., Blankenship, A., Overall, R., Staufenbiel, M. & Kempermann, G. (2006) Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer’s disease. Biol Psychiatry 60, 13141323.
  • Wolfe, M.S. & Kopan, R. (2004) Intramembrane proteolysis: theme and variations. Science 305, 11191123.
  • Wynn, Z.J. & Cummings, J.L. (2004) Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer’s disease. Dement Geriatr Cogn Disord 17, 100108.
  • Yamada, T., Yoshiyama, Y. & Kawaguchi, N. (1997) Expression of activating transcription factor-2 (ATF-2), one of the cyclic AMP response element (CRE) binding proteins, in Alzheimer disease and non-neurological brain tissues. Brain Res 749, 329334.
  • Yamamoto-Sasaki, M., Ozawa, H., Saito, T., Rosler, M. & Riederer, P. (1999) Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res 824, 300303.
  • Yankner, B.A., Caceres, A. & Duffy, L.K. (1990) Nerve growth factor potentiates the neurotoxicity of beta amyloid. Proc Natl Acad Sci U S A 87, 90209023.